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Introduction
Increasing evidence indicates that cancer arises from a stepwise accumulation of genetic changes and that the incipient cancer cells acquire mutant alleles of tumor-suppressor genes and/or proto-oncogenes 1 . Genetic alterations observed in cancers include point mutations, chromosomal number alterations, chromosomal translocations, and gene deletions or amplifications 2 . A number of human cancers have deletions and/or point mutations at specific gene loci, causing the putative inactivation of tumor-suppressor genes. Thus, elucidation of the molecular mechanisms underlying the genetic alterations that occur at the loci encoding tumor-suppressor proteins is important to gain a better understanding of tumorigenesis.
A novel mechanism of genetic alterations, i.e., DNA/RNA editing by members of cytidine deaminases, was recently reported [3] [4] [5] . Among the 11 human cytidine deaminases identified, activation-induced cytidine deaminase (AID) is the only molecule that exerts genetic effects on human DNA sequences under physiologic conditions. AID is an essential enzyme for somatic hypermutation, class switch recombination (CSR), and gene conversion, all of which are crucial steps to achieve the diversification of the immunoglobulin (Ig) genes in activated B lymphocytes 3 . In sharp contrast to the physiologic role of AID in the editing of the Ig genes, we recently demonstrated a pathologic role of AID linking the accumulation of nucleotide alterations in tumor-related genes and human cancer development [6] [7] [8] . Indeed, aberrant expression of AID is induced in response to pro-inflammatory cytokine stimulation in gastric epithelial cells, colon epithelial cells, biliary ductal cells, and hepatocytes and leads to the accumulation of somatic mutations in various tumor-related genes in vitro [9] [10] [11] [12] [13] . Moreover, we showed that infection with
Helicobacter pylori (H.pylori), a class one carcinogen for gastric cancer, induces aberrant AID expression in gastric epithelial cells, resulting in the accumulation of TP53 tumor suppressor gene mutations 13 . Consistent with these in vitro findings, a mouse model with continuous and 5 ubiquitous expression of AID develops cancers in several epithelial organs, including stomach, liver, and lung, via the accumulation of somatic mutations [14] [15] [16] . These findings elucidated a novel molecular mechanism linking inflammation, genetic mutations, and cancer development.
Because AID can trigger a CSR of the Ig gene, it is reasonable to assume that AID can also mediate chromosomal aberrations by triggering double-strand DNA breaks (DSBs) in lymphoid cells, in addition to somatic point mutations. Indeed, recent studies revealed that AID is required for the generation or accumulation of chromosomal translocations during lymphoma development 17 . For example, translocations between c-myc and the IgH locus (Igh) are induced in primary B cells within hours of AID expression, while c-myc-Igh translocations are absent in AID-deficient mice [18] [19] [20] [21] [22] [23] . These findings prompted us to speculate that aberrant expression of AID in epithelial cells might cause not only somatic point mutations but also chromosomal alterations, both of which would play critical roles in the activation and/or inactivation of tumor-related genes. In this study, therefore, we investigated whether the genotoxic activity of AID could underlie the emergence of genetic aberrations at specific chromosomal loci encoding tumor-related proteins in human gastric epithelial cells and thus contribute to the development of gastric cancers.
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software. Agilent CGH Analytics software was used to identify regions of copy number alteration.
Fluorescence in situ hybridization (FISH) analysis
DNA probes specific to CDKN2b-CDKN2a locus and ELAVL2 gene were amplified using the primers shown in Supplementary Table 1 . These probes were labeled by nick-translation with either SpectrumGreen-or SpectrumOrange-labeled dUTP and hybridized to chromosomes of AGS cells expressing AID for 21 days. Images were taken with the fluorescence microscope MD5000B (Leica, Wetzlar, Germany).
DNA polymorphism analysis
The DNA polymorphism analyses of restriction fragment length polymorphisms were performed to detect loss of heterozygosity (LOH). PCR was performed using the primer sets shown in Supplementary Table 1 , and PCR products were digested with Dde I (for human CDKN2A) or Psp 1406 I (for human CDKN2B).
Southern blot analysis
Southern blot analysis of the PCR products was performed using AlkPhos Direct Labelling Reagents (GE Healthcare, Buckinghamshire, UK), with DNA probes labeled using alkaline phosphatase, according to the manufacturer's protocol. The primer sets used are shown in Supplementary Table 1 .
Subcloning and sequencing of tumor-related genes
The oligonucleotide primers used are shown in Supplementary Table 1 . Amplification of the target sequences was performed using high-fidelity Phusion Taq polymerase (Finnzymes, Espoo, Finland), and the products were subcloned into a pcDNA3 vector (Invitrogen, Carlsbad, CA).
The resulting plasmids were subjected to sequence analysis 11 .
Patients
The study group comprised 28 Repeated CGH analyses on AGS cells showed that deletions at two specific loci, 9p21 and 3q27, commonly occurred after 1-week and 3-week AID activation, though there were many deleted regions observed. Notably, these chromosomal regions harbored the tumor-suppressor genes cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase inhibitor 2B
(CDKN2B) at 9p21, and B-cell CLL/lymphoma 6 (BCL6) at 3q27 ( Figure 1A ). It has been well recognized that CDKN2A and CDKN2B play crucial roles as tumor-suppressor genes in the development of various human tumors 29 . Therefore, we further examined whether AID expression caused the deletion of the CDKN2b-CDKN2a locus at 9p21 using fluorescence in situ hybridization (FISH) analyses with the probes specific for CDKN2b-CDKN2a locus and control ELAVL2 gene. We found that significantly more deletions of CDKA2b-CDKN2a locus were present in human gastric cells with AID activation than those in the control cells (27.6% and 6.9%, respectively; P < 0.001; Figure 1B and Table 1 ). In contrast, there was no significant difference in the frequency of deleted signals for ELAVL2 gene between AID-expressing cells and cells without AID activation (11.9% and 11.2%, respectively; Table 1 ). These results suggest that AID preferentially induces submicroscopic deletions of CDKN2A and CDKN2B genes in gastric epithelial cells.
Next, we analyzed the gastric mucosa of AID Tg mice, which develop various tumors, including gastric cancer, in association with the accumulation of somatic mutations 16 . We (Table 2 ). In contrast, gastric cells with AID activation had significantly higher frequencies of nucleotide alterations in the CDKN2A and CDKN2B genes than those in control cells (P < 0.01; Table 2 ). Of the 19 mutations in CDKN2A of AID-activated AGS cells, 1 was a nonsynonymous mutation and another was a frameshift mutation resulting in loss of function. Three of 11 mutations in CDKN2B of AID-activated AGS cells were nonsynonymous mutations. Substantially higher mutation frequency was also observed in the BCL6 gene in the cells with AID activation than that in control cells (Table 2) . Similar findings were obtained by analyses of the gastric mucosa from AID Tg mice.
We detected only a single or two nucleotide alterations in either of the Cdkn2a or Cdkn2b genes in the gastric mucosa of WT mice (Table 3) . In contrast, a number of somatic mutations were induced in the Cdkn2a and Cdkn2b genes in the gastric mucosa of AID Tg mice (Table 3) .
Significantly higher frequencies of nucleotide alterations in Cdkn2a and Cdkn2b genes were detected in non-cancerous tissue as well as in gastric cancer in AID Tg mice than in control gastric tissue from WT mice (P < 0.01; Table 3 ). Interestingly Taken together, these findings suggested that AID-triggered genotoxic effects were preferentially aimed at the CDKN2A and CDKN2B genes, and induced both submicroscopic deletions and nucleotide alterations of these tumor-suppressor genes in gastric epithelial cells. Figure 3) , and determined the relative copy number ratios of the Cdkn2a and Cdkn2b genes in the gastric mucosa. We first confirmed that oral infection of H.pylori in WT mice upregulated AID expression in the gastric mucosa ( Figure 3A , upper panel), whereas endogenous AID expression was undetectable in uninfected mouse stomach ( Figure 3A, upper panel) or in AID-deficient mice with H.pylori infection ( Figure 3D, upper panel) .
H. pylori infection triggered the loss of the
Interestingly, relative copy number ratios of Cdkn2a were significantly lower in most of the stomachs of WT mice infected with H.pylori, compared with uninfected mice (P < 0.05; Figure   3B ). Similarly, there was a significant reduction in the copy number ratio of the Cdkn2b gene in the gastric mucosa in association with H.pylori infection, compared with the mice without H.pylori infection (P < 0.05; Figure 3C ). In contrast, there was no change in the relative copy number ratio of the Cdkn2a and Cdkn2b genes in the stomach of AID-deficient mice with Previous studies revealed that epigenetic changes in the promoter region contribute to the downregulation of CDKN2A or CDKN2B gene expression, leading to inactivation of these tumor-suppressor genes in various human cancers [30] [31] [32] [33] . In contrast, little is known about the genetic alterations in CDKN2A and CDKN2B genes during human gastric cancer development.
Thus, we analyzed the relative copy number ratios of CDKN2A and CDKN2B in H.pylori-positive human gastric cancer clinical specimens. The relative copy number ratio of the CDKN2A or CDKN2B genes was reduced to less than half in 10 of 28 (36%) tumors compared with those of the surrounding non-tumorous gastric mucosa of patients with gastric cancers, and the copy number of the CDKN2A or CDKN2B genes was significantly lower in tumorous tissue than in surrounding non-tumorous gastric mucosa among these cases (P < 0.05; Figure 4A and B).
Real-time RT-PCR analyses revealed that the expression levels of both CDKN2A and CDKN2B
transcripts were significantly lower in tumorous tissues than in non-tumorous gastric mucosa in the clinical specimens with CDKN2A and CDKN2B gene copy number reductions ( P < 0.05 ;
Supplementary Figure 5A and B). Southern blot analyses revealed that genetic signals derived from the CDKN2A gene in cancer tissues were substantially smaller than those in the surrounding non-cancerous gastric mucosa of the 10 patients with the reduced levels of CDKN2A
and CDKN2B copy numbers ( Figure 4C , upper panel). In addition, DNA polymorphism analyses showed that LOH in CDKN2A or CDKN2B gene was detectable in 4 of 10 gastric cancer tissue specimens examined ( Figure 4D and E). Taken together, these findings suggested that submicroscopic deletions of the CDKN2b and CDKN2a loci were present in a subset of human gastric cancer tissues.
Discussion
Various genetic alterations contribute to the inactivation of tumor-suppressor genes during cancer development. We previously demonstrated that H.pylori infection and the resultant inflammatory response ectopically induce AID expression in human gastric epithelial cells, leading to the generation of somatic mutations in various tumor-related genes such as TP53 13 .
On the other hand, deletion of specific chromosomal loci is another major genetic event that
inactivates tumor-suppressor genes 34 . 39 . The deletion at chromosome 9p21 in humans, which removes the CDKN2A tumor-suppressor gene, is a genetic alteration frequently observed in several human cancers 40 , prompting speculation that biochemical pathways regulated by these proteins must be disabled for normal cells to be transformed into tumor cells 39 . Consistent with these findings, we previously demonstrated that AID expression in biliary cells induces somatic mutations in the promoter region of the CDKN2A gene 10 . Thus, the CDKN2b-CDKN2a locus might be a common target for AID-mediated genotoxic effects in both gastric and biliary epithelial cells.
In sharp contrast to the CDKN2b-CDKN2a locus, few of the other genes examined exhibited a common susceptibility to AID-mediated genotoxic effects in human and mouse gastric epithelial cells. It should be noted that the human CDKN2b-CDKN2a locus is located on chromosome band 9p21, while the cognate locus of the mouse genes is present on chromosome 4 41 . The reason for the selective AID attack of the CDKN2b-CDKN2a locus in both humans and mice irrespective of the chromosomal region, is not clear. Consistent with the hypothesis that the CDKN2A deletion is triggered by AID activity, previous structural analyses of breakpoints for CDKN2A deletions in human cancers revealed that DSBs triggering deletions in leukemia cells are formed at a few defined sites by the illegitimate action of the RAG protein complex, while DSBs in solid tumors are formed at nonspecific sites in or near the CDKN2a locus by undefined factors 40 . It was recently demonstrated that AID expression is required to introduce DNA single-strand breaks into both rearranged IgH variable-region genes and the CDKN2B gene in leukemia cells 42 , and frequent deletion of CDKN2A and CDKN2B was also reported in the AID-positive lymphoid blast crisis leukemia cells 43 . In support of these findings, we confirmed that the upstream sequences of the CDKN2b-CDKN2a locus carries E box motifs (CAGGTG), which are tightly associated with AID hypermutation activity at both Ig and non-Ig genes 44 , at very high density (11 motifs within 10 kbp sequences). Together these findings suggest that there are AID-preferential motifs in the sequences around the CDKN2a locus in both human and mouse, and thus the genotoxic activity of AID triggers preferential chromosomal deletions as well as somatic point mutations in the CDKN2b-CDKN2a locus.
A number of tumor suppressor genes exhibit epigenetic changes with resulting gene silencing in cancers and it is well recognized that the CDKN2A gene is frequently inactivated by aberrant methylation 32, 45 . In contrast, little is known about the genetic changes in the CDKN2A
and CDKN2B genes in human gastric cancers. Here we demonstrated that copy number losses of the CDKN2b-CDKN2a locus were present in a subset of human gastric cancer tissues. We also showed that H.pylori infection triggered a reduction in the copy numbers of the Cdkn2a and
Cdkn2b genes in the gastric mucosa of WT mice, and strikingly, the alterations of the 
Deleted genes
Data represent the frequency of chromosomes with the deletions of targeted genes, and values in parentheses indicate number of chromosomes with deleted genes per number of total chromosomes examined. *, P < 0.001, vs. control. CDKN2A, CDKN2B and BCL6 sequences were amplified from AGS cells with or without AID activation for 21 days, followed by analysis of nucleotide sequences in randomly selected clones. Data represent mean mutation frequency (left), number of mutated bases per number of total base pairs sequenced (middle, in parentheses), and number of mutated clones per number of total clones examined (right). *, P < 0.01, vs. control. 
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